Philogen Raises €62m To Advance Pipeline, Expand GMP Capacity

 
• By Sten Stovall

Philogen CEO Dario Neri tells Scrip the company he co-founded now has two oncology products in Phase III development and might consider partnering them for certain indications.

R&D
Philogen develops drugs for the treatment of angiogenesis-related disorders • Source: Shutterstock

More from Clinical Trials

More from R&D